Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.44 |
| ▸ | CDK9 | P50750 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929787 | 1.00 | CCNT1 (0.44) | CCNT1CDK9HTR2AHTR2CSLC6A2 | |
| SCHEMBL4929791 | 1.00 | CCNT1 (0.44) | CCNT1CDK9HTR2AHTR2CSLC6A2 | |
| SCHEMBL4890808 | 0.85 | SLC6A2 (0.39) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4883057 | 0.85 | HTR6 (0.44) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4883064 | 0.85 | HTR6 (0.44) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4890816 | 0.85 | SLC6A2 (0.39) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4890823 | 0.85 | SLC6A2 (0.39) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4883070 | 0.85 | HTR6 (0.44) | HTR2AHTR2CSLC6A2SLC6A4HRH1 | |
| SCHEMBL4726656 | 0.83 | HTR2A (0.64) | HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL4726674 | 0.83 | HTR2A (0.64) | HTR2AHTR2CSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | CCNT1 2749/4885CDK9 710/4885HTR2A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.